Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s): DHTRF

Healthcare Biotechnology

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.

TSX:DHT.UN - Post by User

Dri Healthcare Trust

<< Previous

Bullboard Posts

Next >>

(25)
•••

Comment by HermannHalleron May 14, 2025 11:25am

41 Views

Post# 36573388

RE:I See The Losers Are Grasping For Straws!

I expect the votes withheld represent someone upset about the CEO/governance issue in the past year. Which is fair. I don't think it's a commentary on the new management and direction forward.

I listened to all the conference calls, and in my view they handled a tough situation well. I think its reasonable that the stock could get back over $15. That would only be back to where it was pre-CEO disclosure, so not unreasonable.